The journal Nature has published the results of a clinical trial led by researchers from the Clínica Universidad de Navarra…
The phase 3 EMBER-3 trial is evaluating imlunestrant, a next-generation oral selective estrogen receptor degrader (SERD), alone or in combination…
The results of the SOLTI-2103 VALENTINE clinical trial demonstrate that the antibody drug conjugate (ADC) patritumab deruxtecan at the standard…
Pancreatic ductal adenocarcinoma (PDAC) is expected to become the second-leading cause of cancer-related deaths in Europe by 2040. Unlike other…
A recent study has provided new insights into how the tumour microenvironment may affect the development of liver metastases in…
The Vall d’Hebron Institute of Oncology (VHIO) has received one of the COFUND grants under the Marie Skłodowska-Curie Actions (MSCA)…
“Maestra con clase” is an initiative created by Mónica Tribó to design materials and products specifically for teachers. In her…
Dr. Jonathan Whitfield and Dr. Mariano Zacarías-Fluck, researchers in the Models of Cancer Therapies Group at VHIO, together with Dr….
Clarivate™ has revealed the annual list of Highly Cited Researchers™ 2024, curated by its experts at the Institute for Scientific…
The p95HER2 protein is found expressed in one third of HER2+ tumors, which represent 4% of all tumors. Led by…
• Endocrine therapy is a type of cancer treatment that slows or halts the growth of hormone-sensitive cancers and is…
The third edition of the VHIOVida Festival, which was held on Saturday October 19, in Cabrils, brought together more than…
